22.6 C
New York
Saturday, June 13, 2026

Tag: population

Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

Reinforces Seer’s Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity

Booking Health Announces Release of Findings on International Access to Personalized Glioblastoma Treatment in Germany

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.

Dr. Crystal Nelson Explains How Genetic Testing Is Transforming Mental Health Medication Treatment on YourUpdateTV

New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Grant & Eisenhofer Representing Dozens of Rhode Island Clergy Sexual-Abuse Survivors Amid Long-Awaited Legislative Reform

GRANT & EISENHOFER FIRM REPRESENTING DOZENS OF RHODE ISLAND CLERGY SEXUAL-ABUSE SURVIVORS AMID LONG-AWAITED LEGISLATIVE REFORM

AMERICAN SKIN ASSOCIATION ANNUAL GALA RECOGNIZES SUN PHARMA WITH CORPORATE LEADERSHIP AWARD

Specialty and Generic Medicines Leader Honored for Dedication to the Dermatology FieldNEW YORK, June 3, 2026 /PRNewswire/ -- On Tuesday evening at The Plaza...

VEON to Release 2Q26 Earnings on July 31, 2026

Dubai and New York, June 3, 2026 – VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or “the Company”), today confirms that it will release its consolidated financial and operating results for the second quarter and half-year ended June 30, 2026, on July 31, 2026.

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

EQT Real Estate expands its growing UK logistics footprint with acquisition of six assets across key distribution hubs

Portfolio comprises six Grade A logistics assets totaling approximately 1.6 million square feet across the West Midlands, East Midlands and South East of the...

Ajay Rajan joins Protean eGov Technologies Ltd. as Managing Director & Chief Executive Officer

Appointment marks the next phase of growth across Digital Public Infrastructure, AI-enabled enterprise solutions and international marketsMUMBAI, India, June 3, 2026 /PRNewswire/ -- Protean...

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

New Research Revealed Effective Surgical Management Techniques for Gynecomastia in Asian Men, Resulting in High Patient Satisfaction

Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles....

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPopulation